July 27, 2020 Regulatory press release Oasmia’s partner Elevar Therapeutics and Tanner Pharma Announce Global Named Patient Program to Provide Access to Apealea® Read more
June 18, 2020 Regulatory press release Oasmia Pharmaceutical AB (publ). Year-end report for the financial year May 1, 2019 – April 30, 2020 Read more
May 14, 2020 Regulatory press release Oasmia Pharmaceutical supplements bulletin from Extraordinary General Meeting Read more
May 14, 2020 Regulatory press release Oasmia Pharmaceutical Announces Results of Extraordinary General Meeting and Board Changes Read more
May 13, 2020 Regulatory press release Oasmia announces outcome of strategic review to deliver long-term, profitable growth as a specialty pharma company Read more
April 17, 2020 Regulatory press release Notice of extraordinary general meeting in Oasmia Pharmaceutical AB Read more
April 17, 2020 Regulatory press release Oasmia Nomination Committee suggest changes in the Board of Directors Read more
March 27, 2020 Regulatory press release Oasmia Pharmaceutical AB (publ) Interim report for the period May 1, 2019 – January 31, 2020 Read more
March 25, 2020 Regulatory press release Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea® with an upfront payment of USD 20 million, milestone payments with a potential of up to USD 678 million and double digit royalties. Read more
